Disparate effects of the combined therapy of empagliflozin and linagliptin versus metformin and insulin glargine on renal haemodynamics in type 2 diabetes

Ott C, Jung S, Kannenkeril D, Striepe K, Bosch A, Korn M, Bramlage P, Schmieder R (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Diabetologia Springer Verlag (Germany)

Publisher: SPRINGER

City/Town: NEW YORK

Pages Range: S40-S40

Conference Proceedings Title: DIABETOLOGIA

Event location: Barcelona ES

Authors with CRIS profile

Christian Ott Medizinische Fakultät Susan Jung Department of Paediatrics and Adolescent Medicine Kristina Striepe Professur für Innere Medizin (Nephrologie) Agnes Bosch Department of Medicine 4 – Nephrology and Hypertension Roland Schmieder Professur für Innere Medizin (Nephrologie)

Involved external institutions

Institut für Pharmakologie und präventive Medizin (IPPMed GmbH) DE Germany (DE)

How to cite

APA:

Ott, C., Jung, S., Kannenkeril, D., Striepe, K., Bosch, A., Korn, M.,... Schmieder, R. (2019). Disparate effects of the combined therapy of empagliflozin and linagliptin versus metformin and insulin glargine on renal haemodynamics in type 2 diabetes. In DIABETOLOGIA (pp. S40-S40). Barcelona, ES: NEW YORK: SPRINGER.

MLA:

Ott, Christian, et al. "Disparate effects of the combined therapy of empagliflozin and linagliptin versus metformin and insulin glargine on renal haemodynamics in type 2 diabetes." Proceedings of the 55th Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), Barcelona NEW YORK: SPRINGER, 2019. S40-S40.

BibTeX: Download